Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Novartis announced one year results from the Phase 3 FUTURE 2 study with Cosentyx (secukinumab) in patients with psoriatic arthritis (PsA). The findings were published in The Lancet.
FUTURE 2 is a multi-center, randomized, placebo-controlled study designed to evaluate the efficacy of IL-17A inhibition with Cosentyx in 397 patients with PsA. The new study results demonstrate that improvements with subcutaneous Cosentyx 300mg and 150mg were sustained over one year of treatment in the majority of patients (64% for both doses). ACR 50 response rates were also sustained to one year in Cosentyx 300mg and 150mg (44% and 39% respectively). Cosentyx met the primary endpoint of the study, which was ACR 20 at Week 24 with response rates significantly higher in the Cosentyx 300mg (54%; P<0.0001) and 150 mg (51%; P<0.0001) groups vs. placebo (15%). Clinical improvements were observed as early as Week 3.
RELATED: Significant Improvement in Plaque Psoriasis Seen With Cosentyx
Cosentyx is a human monoclonal antibody (mAb) that selectively binds to and neutralizes IL-17A. It is currently indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
For more information call (800) 693-9993 or visit Novartis.com.
